Latest News and Press Releases

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025